David Rosa

Chief Executive Officer; Board of Directors

Dave Rosa is Sunshine Heart's Chief Executive Officer. Mr. Rosa has spent the past 19 years in a variety of positions in the medical device industry. He was appointed CEO in October of 2009.

Prior to joining Sunshine Heart, he was President and CEO of Milksmart, Inc., a privately held company developing a unique stent-like agricultural technology that increases milking efficiencies, output and quality. From 2004-2008, Rosa was Vice President of Global Marketing for Cardiac Surgery and Cardiology at St. Jude Medical, Inc. While at St. Jude, he directed the launch of twenty seven new products within the Company's cardiovascular division.

From 1999-2004, Rosa held executive management positions at privately held A-Med Systems, Inc., an emerging medical technology company that designs, develops and commercializes percutaneously placed ventricular assist devices (pVADs) for acute heart failure. His roles included Vice President of Marketing and Sales, Senior Vice President of Marketing and Business Development, Chief Operating Officer and Chief Executive Officer. From 1995- 1999, he served as Product Manager for Angioplasty Balloons and Director of Intravascular Ultrasound at SCIMED Life Systems, a privately held company that was engaged in the development, manufacture and marketing of medical devices to treat cardiovascular disease. SCIMED was acquired by Boston Scientific Corporation and now operates as a subsidiary of Boston Scientific.

Mr. Rosa holds an M.B.A. in Marketing Management from Duquesne University and a B.S. in Commerce and Engineering from Drexel University.

William Peters, MD

Medical Director & Chief Technical Officer; Board of Directors

William Peters, MD, invented the proprietary C-Pulse technology and served as Sunshine Heart’s initial CEO upon co-founding the Company in 1999. As Medical Director and Chief Technical Officer, he is responsible for C-Pulse’s ongoing technological development and clinical application as an innovative technology for treating moderate heart failure.

In addition to C-Pulse, Dr. Peters has developed a number of other successful cardiac technology innovations, including an endovascular cardiopulmonary bypass system for minimally invasive cardiac surgery, which was commercialized by Heartport Inc., a NASDAQ-listed company that later was acquired by Johnson & Johnson.

Dr. Peters has been the lead or co-author of more than 20 published articles, and contributed chapters to four books regarding cardiac surgery and heart failure. He has extensive clinical experience in thoracic transplantation and a variety of heart failure technologies, including intra-aortic balloon pump systems and left-ventricular assist devices (LVADs) from such companies as Biomedicus, Abiomed, Thoratec and World Heart-Novacor. He has an honorary appointments with the University of Auckland's department of surgery and biomedical engineering, providing supervision of doctoral candidates. He is also a senior clinical research fellow in cardiothoracic surgery, based at Auckland City Hospital. These roles afford Sunshine Heart a direct view of the latest developments, particularly in the fields of congestive heart failure and biomedical engineering advancement.

Debra Kridner

Vice President Clinical Research and Regulatory Affairs

Debra Kridner joined Sunshine Heart in November 2009 as Vice President, Clinical Research and Regulatory Affairs. Kridner brings more than 30 years of experience in clinical research, quality and regulatory affairs for the medical device industry.

Prior to joining Sunshine Heart, Kridner owned a consulting firm focused on clinical research and regulatory affairs. Before founding her own business, she served as Vice President, Clinical Research and Regulatory Affairs for Cardiac Surgery and Interventional Cardiology for the Cardiovascular Division of St. Jude Medical, Inc. Prior to St. Jude, Kridner held senior management positions in clinical, regulatory, and quality at Medtronic in the areas of cardiac surgery and neurology.

In addition Kridner also held executive management position as the Vice President of Regulatory and Quality for Medsource, an eleven facility medical device contract manufacturer. Her career also included several medical and scientific research and development companies including Edwards Lifescience/Baxter Edwards and, Gish Biomedical.

Debra is also on the Advisory Board for the St. Cloud University Masters Degree Program for Clinical Research and Regulatory Affairs. Kridner holds a B.A. in Biology from University of California Fullerton.

Kevin Bassett

Vice President Research, Development and Quality Assurance

Kevin Bassett joined Sunshine Heart in October 2010 as Vice President of Research, Development, and Quality Assurance.

Prior to joining Sunshine Heart, Mr. Bassett was Sr. Vice President of Operations, Development, and Quality Assurance at Acorn Cardiovascular, an early-stage medical device company developing passive restraint therapies to treat heart failure. During his seven years with Acorn, he served in a variety of executive level positions encompassing operations, research, development, quality, manufacturing and finance.

From 1997-2004, Mr. Bassett was a Co-founder and Principal at St. Paul Consulting LLC, a firm focused on the medical device and pharmaceutical industries and specializing in operations, development, regulatory affairs, and quality assurance. From 1994-1997 he served as a Senior Consultant and Manager in the management consulting division of Grant Thornton LLC. From 1992-1994 Mr. Bassett was a Senior Consultant at Andersen Consulting LLC (now Accenture LLC).

Mr. Bassett is a certified public accountant (inactive license). He holds an M.B.A. from the Carlson School of Management at the University of Minnesota and a B.A. degree in Accounting and English from St. John’s University. Mr. Bassett also held a commission as an officer in the United States Army Reserves from 1991 – 2001.

Jeff Mathiesen

Chief Financial Officer

Jeff Mathiesen joined Sunshine Heart as Chief Financial Officer (CFO) in March 2011. He brings more than 20 years experience as a finance and operations officer with extensive background managing finance, manufacturing, administration, information technology, human resources, investor relations and risk management functions in diverse, publicly and privately held companies.

Prior to Sunshine Heart, Mathiesen served as Vice President and CFO for Zareba® Systems, Inc., a publicly held manufacturer and marketer of medical products, perimeter fencing and security systems. At Zareba, he helped the company change course and return to profitability, led the divestiture of two business units and helped negotiate the sale of the company to Woodstream Corp., a long-standing, privately held company.

Before Zareba® Systems, Mathiesen had served in numerous other finance and operations leadership roles in high growth, technology based, publicly held companies with operations around the globe. His experience includes several public and private equity financings including an IPO, and various M&A transactions. Previous positions held by Mathiesen include Vice President and CFO for Delphax Technologies, Inc.; Vice President of Business Development, Vice President, and CFO for Micro Component Technology, Inc.; Vice President and CFO Recovery Engineering, Inc., subsequently acquired by Proctor & Gamble; Corporate Controller at Osmonics, Inc., subsequently acquired by General Electric Company; and Aslesens, Inc., as a controller.

Mathiesen is a certified public accountant who started his career at Deloitte & Touche, LLP, after completing a B.S in Accounting at the University of South Dakota.

Jim Yearick

Vice President of Marketing and Sales

Jim Yearick joined Sunshine Heart as Vice President of Marketing and Sales, October, 2011. He brings 19 years of medical device leadership in marketing/sales management.

Prior to joining Sunshine Heart, Yearick held executive roles for 8 years at Medtronic’s Cardiac Rhythm Disease Management Division. From 2008-2011 he was Vice President of Global Product Marketing managing the Therapy Product lines, Healthcare Economics, Reimbursement, Pricing, International Marketing and U.S. Field Marketing. From 2005-2008, Yearick served as the Vice President, Asia with General Management responsibility for 4 regions spanning 12 countries and was based out of Hong Kong. Previous to this role he was a Field Director for the Eastern Region.

In addition, Yearick held Marketing and Sales leadership roles with Genzyme (2000-2003) as Director of International Markets and previous to that was with Boston Scientific (1992 – 2000) in a variety of roles. Previous to joining the medical device field he held leadership roles with both Unilever and Procter & Gamble.

Yearick holds an MBA from Northeastern University and a BSBA Degree from the University of Delaware.

Board of Directors

Nicholas Callinan

Chairman

Mr. Callinan is the founder and managing partner of Collins Hill Pty Ltd., which provides advice to institutional investors and funds managers in the global private equity and venture capital markets where he has worked for over 20 years in several countries including the UK and USA. In the early 1990’s he set up investment funds in the former communist countries of Central Europe. Previously in the early 1980’s he was founder and chief executive of the Advent group of companies, which were one of the first venture capital investment groups in Australia. He has served on a number of company boards both private and public, government bodies and charitable foundations in Australia and overseas. He has degrees in Engineering and Business Administration from the University of Melbourne. Mr. Callinan joined the Sunshine Heart board mid-year 2008 and was appointed Chairman in October 2008.

Geoffrey Brooke, MD

Non-executive Member

Dr. Brooke is managing director of GBS Venture Partners Ltd., which manage A$150 million in early stage venture funds. Previously, he was Managing Director of GBS when it was a part of the Rothschild Group, until he and another partner purchased the business in 2002. Prior to joining Rothschild, Dr. Brooke worked with Johnson & Johnson to co-found MedVest Inc., a US-based early stage venture capital group.

With more than 15 years of venture capital experience, Dr. Brooke has been the founder, lead investor and director of US- and Australian-based healthcare and bioscience companies, many of which have been sold or undertaken IPO’s on the NASDAQ or ASX.

A medical graduate of the University of Melbourne with several years of clinical experience, Dr. Brooke also holds an MBA from IMEDE (now IMD) in Switzerland. He became a Director of Sunshine Heart in 2002.

Donal O'Dwyer

Non-Executive Member

Donal O'Dwyer relocated to Australia after retiring as Worldwide President of Cordis Cardiology, the cardiology division of the Johnson & Johnson subsidiary.

Under his leadership, Cordis Cardiology became the dominant leader in the global stent marketplace, launching the revolutionary Cypher drug eluting coronary stent, which increased global sales from US $500 million to US $2 billion in three years' time.

Prior to joining Cordis, O'Dwyer spent a number of years with Baxter Healthcare, rising from plant manager In Ireland to President of the Cardiovascular Group, Europe. He brings a wealth of medical device experience and became the Company Director in 2004.

Paul Buckman

Non-Executive Member

Mr. Buckman brings more than three decades of medical industry leadership. Paul is currently at Pathway Medical, where he served as chairman of the Board of Directors prior to becoming president and CEO. He joined the company from Devax, Inc. where he served as chief executive officer and board member since December 2006. From August 2004 to December, 2006, Mr. Buckman was president of the Cardiology Division of St. Jude Medical, Inc., a diversified medical products company. Prior to St. Jude Medical, he served as chairman of the Board of Directors and chief executive officer of ev3, LLC, a Minnesota-based medical device company focused on endovascular therapies that Paul founded and developed into an $80 million business. Paul’s 30 years in the medical device industry include 10 years at Scimed Life Systems, Inc. and Boston Scientific Corporation, where he held several executive positions before becoming president of the Cardiology Division in January 2000.

Paul currently serves as a board member for SentreHeart, Inc., Devax, Conventus, and Bio-Star Ventures, and has held posts on the boards of Velocimed, Inc., where he was a co-founder, EndiCor, Inc., Microvena, Inc. and Micro Therapeutics, Inc.

Greg Waller

Non-Executive Member

Mr. Waller has over 35 years of financial and management experience with an emphasis in financial management, accounting, treasury and mergers/acquisitions. Greg was Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories, from March, 2006 until April of 2011 where he implemented several cost savings initiatives that saved the company several millions of dollars. Previous to that, he had been in retirement except for board positions. Prior, Mr. Waller served as the Chief Financial Officer, Vice President of Finance and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products. At Sybron he was instrumental in a variety of initiatives including being instrumental in the IPO of the company, over 30 company acquisitions worldwide and sales growth from $10 million to over $750 million during his twenty-five year tenure at Sybron. He was the Vice President of European Operations for Kerr (a subsidiary of Sybron) and Vice President and Controller at Ormco (also a subsidiary of Sybron) during his time at Sybron. Mr. Waller has an MBA with a concentration in accounting from California State University, Fullerton.

Greg currently serves as a board member and audit committee chairman for Endologix, Inc. He previously served as board member and audit committee chairman for Alsius, Inc., Biolase, Inc., Cardiogenesis Inc., Clarient, Inc. and SenRx, Inc., all publicly traded companies.

Mark Harvey

Non-Executive Member